<DOC>
	<DOCNO>NCT01873417</DOCNO>
	<brief_summary>The primary objective study evaluate effect symptomatic therapy gastrointestinal ( GI ) -related event report participant relapse form multiple sclerosis ( MS ) initiate therapy dimethyl fumarate ( DMF ) clinical practice set . The secondary objective study follow : - To evaluate GI-related event require symptomatic therapy role therapy time participant relapse form MS initiate therapy DMF clinical practice set . - To evaluate GI-related event lead DMF discontinuation use symptomatic therapy participant relapse form MS initiate therapy DMF clinical practice setting .</brief_summary>
	<brief_title>Phase 4 Gastrointestinal Tolerability Study Dimethyl Fumarate Patients With Relapsing Forms Multiple Sclerosis United States</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Decision treat DMF must precede enrollment . Na√Øve DMF fumaric acid ester . Resides US confirm diagnosis relapse form MS. Satisfies approve therapeutic indication ( ) DMF . Key Inability comply study requirement , discretion Investigator , deem unsuitable study participation . History significant GI disease , chronic use GI symptomatic therapy , active malignancy . Is participate interventional clinical trial . NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>